Keywords
Last Name

Karen H. Antman, MD

TitleProvost
InstitutionBoston University Medical Campus
Address72 E. Concord St Instructional (L)
Boston MA 02118
Phone(617) 638-5300
ORCID ORCID Icon0000-0002-1093-8356
Other Positions
TitleDean of School of Medicine
InstitutionBoston University School of Medicine

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHematology & Medical Oncology

TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

 Awards and Honors

Start-EndDescription
Phi Beta Kappa: Member
1994 Voted by Medical Residents, Columbia-Presbyterian Medical Center: Senior Faculty Teacher of the Year
1997American Association for the Advancement of Science: Elected to Fellowship
2001American Association of Professors: Member
2008American Society of Clinical Oncology : Distinguished Service Award for Scientific Leadership
2011Institute of Medicine: Member
 Research Expertise & Professional Interests
Dr. Karen Antman, an internationally recognized expert on breast cancer, mesotheliomas and sarcomas, is Provost of the Medical Campus and Dean of Boston University School of Medicine since 2005. Dr. Antman previously served as Deputy Director for Translational and Clinical Sciences at the National Cancer Institute of the National Institutes of Health (NIH) (2004-5) and before that as Wu Professor of Medicine and Pharmacology and Director of the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons, where she also co-directed the cancer care service line at New York Presbyterian Hospital. Dr. Antman was voted 1993 Senior Faculty Teacher of the Year by medical residents. She also served on the faculty of Harvard Medical School from 1979 to 1993, and had hospital appointments at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston.

Based on her group’s translational research, Dr Antman developed now standard regimens for the treatment of sarcomas and mesotheliomas as well as regimens for breast cancer and supportive care of patients receiving chemotherapy including pharmacology, growth factors and mobilization of peripheral blood derived stem cells for blood and marrow transplant. Dr. Antman also is outspoken on public health policy issues. She has written extensively about impediments to clinical research on cancer, and she has testified before Congress on the need for federal research dollars to support cancer research with articles in the medical literature (as well as Vogue and Readers Digest). She has written more than 300 journal papers and edited five textbooks and monographs, many with multiple editions.

She is a member of PBK and the Institute of Medicine. She has served as President of the American Society of Clinical Oncology in 1994-5, the American Society of Blood and Marrow Transplant in 1996-7, and the American Association for Cancer Research in 2003-4.

She has more than 300 publications and is the editor of 5 textbooks and monographs (Asbestos related malignancies, Sarcomas of Bone and Soft Tissue, High-dose cancer therapy: pharmacology, hematopoietins and stem cells (3 editions), and Molecular Targeting in Oncology).

She serves on the Administration Board of the American Association of Medical Colleges Council of Deans, the Journal of the American Medical Association Oversight Committee, the International Editorial Board of Lancet, and on the board of the Educational Commission for Foreign Medical Graduates (ECFMG). She has served as an associate editor of the New England Journal of Medicine, and on the Council of the National Institutes of Health’s Fogarty International Center.

She has published reviews and editorials on medical policy and the impact of research funding and managed care on American clinical research and testified before congressional subcommittees on eight occasions on National Institutes of Health (NIH) appropriations and medical policy.

 NIH RePORTER Grants

Yr Title Project-Sub Proj Pubs
2008 General Clinical Research Center 5M01RR000533-40 429
2007 General Clinical Research Center 2M01RR000533-39 429
2006 GENERAL CLINICAL RESEARCH CENTER 5M01RR000533-38 429
2005 GENERAL CLINICAL RESEARCH CENTER 5M01RR000533-37 429
2002 CORE--CLINICAL TRIALS CORE FACILITY 5P30CA013696-30-9035 181
2002 CORE--CLINICAL TRIALS CORE FACILITY 3P30CA013696-30S2-9035 181
2002 CORE--CLINICAL TRIALS CORE FACILITY 3P30CA013696-30S1-9035 181
2002 CORE--CLINICAL TRIALS CORE FACILITY 3P30CA013696-29S2-9035 181
2002 COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM 5U10CA068183-08 64
2002 CANCER CENTER SUPPORT GRANT 3P30CA013696-30S2 181
Showing the 10 most recent of 49 results. Show All Results

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
    View in: PubMed
  2. Levine AS, Alpern RJ, Andrews NC, Antman K, Balser JR, Berg JM, Davis PB, Fitz JG, Golden RN, Goldman L, Jameson JL, Lee VS, Polonsky KS, Rappley MD, Reece EA, Rothman PB, Schwinn DA, Shapiro LJ, Spiegel AM. Research in academic medical centers: two threats to sustainable support. Sci Transl Med. 2015 May 27; 7(289):289fs22. PMID: 26019216.
    View in: PubMed
  3. Stiff PJ, Agovi MA, Antman KH, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M. High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant. 2010 Apr; 16(4):525-32. PMID: 19961947.
    View in: PubMed
  4. Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010 Apr 20; 28(12):2058-63. PMID: 19687327.
    View in: PubMed
  5. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S. Specific barriers to the conduct of randomized trials. Clin Trials. 2008; 5(1):40-8. PMID: 18283079.
    View in: PubMed
  6. Murabito JM, Rosenberg CL, Finger D, Kreger BE, Levy D, Splansky GL, Antman K, Hwang SJ. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet. 2007; 8 Suppl 1:S6. PMID: 17903305.
    View in: PubMed
  7. Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9. PMID: 16600983.
    View in: PubMed
  8. Antman K, Hassan R, Eisner M, Ries LA, Edwards BK. Update on malignant mesothelioma. Oncology (Williston Park). 2005 Sep; 19(10):1301-9; discussion 1309-10, 1313-6. PMID: 16285225.
    View in: PubMed
  9. Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. Cancer. 2004 Feb 15; 100(4):818-25. PMID: 14770440.
    View in: PubMed
  10. Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Cancer. 2003 Jul 15; 98(2):331-6. PMID: 12872353.
    View in: PubMed
  11. Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Elfenbein G, Horowitz MM, Antman KH. Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. Bone Marrow Transplant. 2003 Jul; 32(2):151-5. PMID: 12838279.
    View in: PubMed
  12. Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003 Feb 1; 97(3):537-44. PMID: 12548594.
    View in: PubMed
  13. Antman K, Abraido-Lanza AF, Blum D, Brownfield E, Cicatelli B, Debor MD, Emmons K, Fitzgibbon M, Gapstur SM, Gradishar W, Hiatt RA, Hubbell FA, Joe AK, Klassen AC, Lee NC, Linden HM, McMullin J, Mishra SI, Neuhaus C, Olopade FI, Walas K. Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium. Breast Cancer Res Treat. 2002 Oct; 75(3):269-80. PMID: 12353816.
    View in: PubMed
  14. Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant. 2002 Aug; 30(3):149-55. PMID: 12189532.
    View in: PubMed
  15. Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002 Feb 28; 346(9):683-93. PMID: 11870247.
    View in: PubMed
  16. Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs. 2002 Feb; 20(1):129-32. PMID: 12003189.
    View in: PubMed
  17. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 1; 20(3):743-50. PMID: 11821456.
    View in: PubMed
  18. Antman K. Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research). Trans Am Clin Climatol Assoc. 2002; 113:56-66; discussion 66-7. PMID: 12053718.
    View in: PubMed
  19. Antman KH. New biology and therapies in soft tissue sarcomas. Biomed Pharmacother. 2001 Nov; 55(9-10):553-7. PMID: 11769966.
    View in: PubMed
  20. Antman K, Benson MC, Chabot J, Cobrinik D, Grann VR, Jacobson JS, Joe AK, Katz AE, Kelly K, Neugut AI, Russo D, Tiersten A, Weinstein IB. Complementary and alternative medicine: the role of the cancer center. J Clin Oncol. 2001 Sep 15; 19(18 Suppl):55S-60S. PMID: 11560974.
    View in: PubMed
  21. Scully RE, Antman KH. Protocol for the examination of specimens from patients with tumors of the peritoneum: a basis for checklists. Arch Pathol Lab Med. 2001 Sep; 125(9):1174-6. PMID: 11520266.
    View in: PubMed
  22. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001 May; 7(5):1192-7. PMID: 11350883.
    View in: PubMed
  23. Antman KH. Randomized trials of high dose chemotherapy for breast cancer. Biochim Biophys Acta. 2001 Mar 21; 1471(3):M89-98. PMID: 11250065.
    View in: PubMed
  24. Antman K, Lagakos S, Drazen J. Designing and funding clinical trials of novel therapies. N Engl J Med. 2001 Mar 8; 344(10):762-3. PMID: 11236782.
    View in: PubMed
  25. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001; 6 Suppl 2:1-2. PMID: 11331433.
    View in: PubMed
  26. Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer. 2001 Jan; 37(2):173-9. PMID: 11166143.
    View in: PubMed
  27. Antman KH. Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer. J Natl Cancer Inst Monogr. 2001; (30):114-6. PMID: 11773303.
    View in: PubMed
  28. Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J. 2000 May-Jun; 6(3):169-78. PMID: 10882333.
    View in: PubMed
  29. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000 Apr 6; 342(14):1027-38. PMID: 10749966.
    View in: PubMed
  30. Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S. An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet. 2000 Jan; 57(1):70-3. PMID: 10733239.
    View in: PubMed
  31. Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am. 2000 Jan-Feb; 6(1):13-20. PMID: 10696733.
    View in: PubMed
  32. Antman KH. High-dose chemotherapy in breast cancer: the end of the beginning? Biol Blood Marrow Transplant. 2000; 6(5):469-75. PMID: 11063376.
    View in: PubMed
  33. Antman KH, Heitjan DF, Hortobagyi GN. High-dose chemotherapy for breast cancer. JAMA. 1999 Nov 10; 282(18):1701-3. PMID: 10568629.
    View in: PubMed
  34. Antman KH. Critique of the high-dose chemotherapy studies in breast cancer: a positive look at the data. J Clin Oncol. 1999 Nov; 17(11 Suppl):30-4. PMID: 10630259.
    View in: PubMed
  35. Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA. 1999 Oct 13; 282(14):1335-43. PMID: 10527180.
    View in: PubMed
  36. Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, Sisti M, Isaacson S, De LaPaz R, Savage DG, Troxel A, Antman KH, Hesdorffer CS. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. J Neurooncol. 1999 Sep; 44(2):155-62. PMID: 10619499.
    View in: PubMed
  37. Antman K, Tiersten A. High-dose chemotherapy for breast cancer: evolving data. Oncology (Williston Park). 1999 Sep; 13(9):1215-9. PMID: 10509318.
    View in: PubMed
  38. Papadopoulos KP, Ayello J, Reiss RF, Troxel A, Kaufman E, Vahdat LT, Antman KH, Hesdorffer CS. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. J Hematother Stem Cell Res. 1999 Aug; 8(4):357-63. PMID: 10634173.
    View in: PubMed
  39. McCarthy P, Hurd D, Rowlings P, Crump M, Gale R, Lazarus H, Vaughan W, Weinberger B, Wiemann M, Freytes C, Cirenza E, Antman K. Autotransplants in men with breast cancer. ABMTR Breast Cancer Working Committee. Autologous Blood and Marrow Transplant Registry. Bone Marrow Transplant. 1999 Aug; 24(4):365-8. PMID: 10467324.
    View in: PubMed
  40. Antman K, Shea S. Screening mammography under age 50. JAMA. 1999 Apr 28; 281(16):1470-2. PMID: 10227298.
    View in: PubMed
  41. Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol. 1999 Apr; 17(4):1175. PMID: 10561176.
    View in: PubMed
  42. Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol. 1999 Feb; 17(2):494-500. PMID: 10080590.
    View in: PubMed
  43. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999 Jan; 10(1):13-9. PMID: 10076716.
    View in: PubMed
  44. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999 Jan; 17(1):423-9. PMID: 10458261.
    View in: PubMed
  45. Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplant. 1998 Oct; 22(7):661-7. PMID: 9818693.
    View in: PubMed
  46. Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res. 1998 Jul; 4(7):1689-95. PMID: 9676843.
    View in: PubMed
  47. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25. PMID: 9667259.
    View in: PubMed
  48. Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clin Cancer Res. 1998 Jun; 4(6):1443-9. PMID: 9626461.
    View in: PubMed
  49. Antman K, Crowley J, Balcerzak SP, Kempf RA, Weiss RB, Clamon GH, Baker LH. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer. 1998 Apr 1; 82(7):1288-95. PMID: 9529020.
    View in: PubMed
  50. Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998 Mar; 16(3):1000-7. PMID: 9508183.
    View in: PubMed
  51. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998 Mar; 16(3):979-85. PMID: 9508180.
    View in: PubMed
  52. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 1998 Jan; 16(1):165-72. PMID: 9440739.
    View in: PubMed
  53. Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec; 3(6):331-40. PMID: 9502301.
    View in: PubMed
  54. Vahdat L, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer. Curr Opin Hematol. 1997 Nov; 4(6):381-9. PMID: 9358993.
    View in: PubMed
  55. Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct; 9(4):361-6. PMID: 9352953.
    View in: PubMed
  56. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997 Oct; 24(5):556-60. PMID: 9344322.
    View in: PubMed
  57. Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer. 1997 Sep 1; 80(5):948-50. PMID: 9307196.
    View in: PubMed
  58. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106. PMID: 9267670.
    View in: PubMed
  59. Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1; 79(11):2237-42. PMID: 9179072.
    View in: PubMed
  60. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997 May; 15(5):1870-9. PMID: 9164197.
    View in: PubMed
  61. Pandita TK, Benvenuto JA, Shay JW, Pandita RK, Rakovitch E, Geard CR, Antman KH, Newman RA. Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function. Biochem Pharmacol. 1997 Feb 7; 53(3):409-15. PMID: 9065745.
    View in: PubMed
  62. Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother. 1997 Feb; 6(1):61-8. PMID: 9112219.
    View in: PubMed
  63. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997 Jan; 111(1):106-9. PMID: 8996002.
    View in: PubMed
  64. Keohan ML, Grever MR, Balcerzak SP, Antman K. A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma. Invest New Drugs. 1997; 15(3):255-6. PMID: 9387048.
    View in: PubMed
  65. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92. PMID: 8918496.
    View in: PubMed
  66. Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, Kaubish A, Vahdat L, Antman K. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother. 1996 Oct; 5(5):549-52. PMID: 8938527.
    View in: PubMed
  67. Antman K. When are bone marrow transplants considered? Sci Am. 1996 Sep; 275(3):124-5. PMID: 8701281.
    View in: PubMed
  68. Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol. 1996 Jul; 14(7):2098-100. PMID: 8683242.
    View in: PubMed
  69. Antman K. Presidential address. May 22, 1995 Thirty-First Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol. 1995 Dec; 13(12):2980-9. PMID: 8523064.
    View in: PubMed
  70. Vahdat L, Antman K. High-dose therapy for breast cancer. Blood Rev. 1995 Sep; 9(3):191-200. PMID: 8563521.
    View in: PubMed
  71. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9. PMID: 7636547.
    View in: PubMed
  72. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50. PMID: 7799026.
    View in: PubMed
  73. Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Antman K, Rosowsky A, Frel E, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36(4):345-51. PMID: 7628055.
    View in: PubMed
  74. Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol. 1994 Oct; 21(5 Suppl 12):83-5. PMID: 7992072.
    View in: PubMed
  75. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G, Begg M. Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther. 1994 Sep; 5(9):1151-60. PMID: 7833373.
    View in: PubMed
  76. Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM, Green MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994 Jul; 12(7):1436-42. PMID: 8021735.
    View in: PubMed
  77. Licht JD, Mazanet R, Loehrer PJ, Gonin R, Antman KH. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1994; 34(1):79-80. PMID: 8174207.
    View in: PubMed
  78. Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr. 1994; (16):91-4. PMID: 7528031.
    View in: PubMed
  79. Lawrence W, Antman K, Freeman HP, Huber SL, Kaufman D, Lantos J, Lenhard RE, Levine RJ, McKenna RJ, Young FE. The impact of clinical trial protocols on patient care systems. Cancer. 1993 Nov 1; 72(9 Suppl):2839-41. PMID: 8402515.
    View in: PubMed
  80. Antman K. Reimbursement issues facing patients, providers, and payers. Cancer. 1993 Nov 1; 72(9 Suppl):2842-5. PMID: 8402516.
    View in: PubMed
  81. Murphy GP, Prestifilippo J, Antman K, Berkman BJ, Huber SL, Kaufman D, Knox WA, Lawrence W, Levine RJ, Young FE. The economic impact of therapy on cancer patients. Cancer. 1993 Nov 1; 72(9 Suppl):2862-4. PMID: 8402521.
    View in: PubMed
  82. Prestifilippo J, Antman K, Berkman BJ, Kaufman D, Lantos J, Lawrence W, Levine RJ, McKenna RJ. The ethical treatment of cancer. What is right for the patient? Cancer. 1993 Nov 1; 72(9 Suppl):2816-9. PMID: 8402510.
    View in: PubMed
  83. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE, Aisner J, Ellison RR, Leone L, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993 Aug; 11(8):1559-65. PMID: 8336195.
    View in: PubMed
  84. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85. PMID: 8315425.
    View in: PubMed
  85. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993 Jun; 11(6):1172-8. PMID: 8501504.
    View in: PubMed
  86. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. PMID: 8099120.
    View in: PubMed
  87. Mentzer SJ, Antman KH, Attinger C, Shemin R, Corson JM, Sugarbaker DJ. Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. J Surg Oncol. 1993 May; 53(1):54-9. PMID: 8479198.
    View in: PubMed
  88. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest. 1993 Apr; 103(4 Suppl):373S-376S. PMID: 8462328.
    View in: PubMed
  89. Elias AD, Ayash L, Skarin AT, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper L, Frei E, Antman KH. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):433S-435S. PMID: 8096454.
    View in: PubMed
  90. Antman KH. GM-CSF in marrow transplantation. Eur J Cancer. 1993; 29A Suppl 3:S2-6. PMID: 8398365.
    View in: PubMed
  91. Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother. 1993; 2(4):507-11. PMID: 7916250.
    View in: PubMed
  92. Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E, Antman K. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother. 1993; 2(3):377-82. PMID: 7522891.
    View in: PubMed
  93. Antman KH, Souhami RL. High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary. Ann Oncol. 1993; 4 Suppl 1:29-44. PMID: 8393339.
    View in: PubMed
  94. Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol. 1992 Dec; 19(6 Suppl 12):13-20. PMID: 1485169.
    View in: PubMed
  95. Fine HA, Antman KH. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant. 1992 Oct; 10(4):315-21. PMID: 1330152.
    View in: PubMed
  96. Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JA, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med. 1992 Sep; 33(9):1594-9. PMID: 1517831.
    View in: PubMed
  97. Demetri GD, Antman KH. Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin Oncol. 1992 Aug; 19(4):362-85. PMID: 1509275.
    View in: PubMed
  98. Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992 Jul; 10(1):57-63. PMID: 1515880.
    View in: PubMed
  99. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992 Jun; 10(6):995-1000. PMID: 1588381.
    View in: PubMed
  100. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol. 1992 Jun; 19(3):317-32. PMID: 1609297.
    View in: PubMed
  101. Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg. 1992 May; 127(5):548-53; discussion 553-4. PMID: 1575625.
    View in: PubMed
  102. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan; 10(1):102-10. PMID: 1727912.
    View in: PubMed
  103. Antman K, Corringham R, de Vries E, Elfenbein G, Gianni AM, Gisselbrecht C, Herzig R, Juttner C, Kaizer H, Kennedy MJ, et al. Dose intensive therapy in breast cancer. Bone Marrow Transplant. 1992; 10 Suppl 1:67-73. PMID: 1355686.
    View in: PubMed
  104. Mazanet R, Antman KH. Adjuvant therapy for sarcomas. Semin Oncol. 1991 Dec; 18(6):603-12. PMID: 1775977.
    View in: PubMed
  105. Antman KH. New developments in clinical oncology: the interdependence of bench and bedside. Cancer Res. 1991 Sep 15; 51(18 Suppl):5060s-5064s. PMID: 1679375.
    View in: PubMed
  106. Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer. 1991 Aug 1; 68(3):463-73. PMID: 2065265.
    View in: PubMed
  107. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6. PMID: 2006519.
    View in: PubMed
  108. Ayash LJ, Antman K, Cheson BD. A perspective on dose-intensive therapy with autologous bone marrow transplantation for solid tumors. Oncology (Williston Park). 1991 Mar; 5(3):25-33; discussion 33, 36, 41. PMID: 1829944.
    View in: PubMed
  109. Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol. 1991; 29(1):61-5. PMID: 1742850.
    View in: PubMed
  110. Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF. Erythropoietin gene regulation: from the laboratory to the bedside. Contrib Nephrol. 1991; 88:35-45; discussion 46-7. PMID: 2040197.
    View in: PubMed
  111. Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1991; 28(3):223-5. PMID: 1830249.
    View in: PubMed
  112. Garber JE, Liepman MK, Gelles EJ, Corson JM, Antman KH. Melanoma and soft tissue sarcoma in seven patients. Cancer. 1990 Dec 1; 66(11):2432-4. PMID: 2245401.
    View in: PubMed
  113. Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 1990 Dec 1; 76(11):2354-9. PMID: 2257306.
    View in: PubMed
  114. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706. PMID: 2213105.
    View in: PubMed
  115. Antman KH. G-CSF and GM-CSF in clinical trials. Yale J Biol Med. 1990 Sep-Oct; 63(5):387-410. PMID: 1705737.
    View in: PubMed
  116. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73. PMID: 2110386.
    View in: PubMed
  117. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990 Apr; 17(2 Suppl 4):41-9. PMID: 2110385.
    View in: PubMed
  118. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol. 1990 Feb; 17(1 Suppl 3):18-32. PMID: 2106164.
    View in: PubMed
  119. Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol. 1990 Feb; 17(1 Suppl 2):7-15. PMID: 2106162.
    View in: PubMed
  120. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol. 1990 Feb; 17(1 Suppl 3):33-8. PMID: 2106166.
    View in: PubMed
  121. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan; 8(1):170-8. PMID: 2104923.
    View in: PubMed
  122. Talcott JA, Thurber WA, Kantor AF, Gaensler EA, Danahy JF, Antman KH, Li FP. Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med. 1989 Nov 2; 321(18):1220-3. PMID: 2552314.
    View in: PubMed
  123. Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (Lond). 1989 Nov; 77(5):501-7. PMID: 2555106.
    View in: PubMed
  124. Antman KH, Eilber FR, Shiu MH. Soft tissue sarcomas: current trends in diagnosis and management. Curr Probl Cancer. 1989 Nov-Dec; 13(6):337-67. PMID: 2689101.
    View in: PubMed
  125. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989 Nov; 1(2):148-54. PMID: 2487155.
    View in: PubMed
  126. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep; 7(9):1208-16. PMID: 2504890.
    View in: PubMed
  127. Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol. 1989 Aug; 16(4):305-11. PMID: 2667145.
    View in: PubMed
  128. Antman KH, Aledort LM, Yarbro J, Wilensky G, Wojcik S, Monaco GP, Windham S. Cost-effectiveness and reimbursement in patient care. Semin Hematol. 1989 Jul; 26(3 Suppl 3):32-45. PMID: 2508228.
    View in: PubMed
  129. Antman KH. Natural history and staging of malignant mesothelioma. Chest. 1989 Jul; 96(1 Suppl):93S-95S. PMID: 2737005.
    View in: PubMed
  130. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May; 7(5):651-61. PMID: 2651580.
    View in: PubMed
  131. Li FP, Dreyfus MG, Antman KH. Asbestos-contaminated nappies and familial mesothelioma. Lancet. 1989 Apr 22; 1(8643):909-10. PMID: 2564999.
    View in: PubMed
  132. Sullivan R, Fredette JP, Socinski M, Elias A, Antman K, Schnipper L, Griffin JD. Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol. 1989 Apr; 71(4):475-9. PMID: 2540792.
    View in: PubMed
  133. Frei E, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors--prospects. J Clin Oncol. 1989 Apr; 7(4):515-26. PMID: 2647915.
    View in: PubMed
  134. Antman KH. Summary of Institute of Medicine study of resources for clinical investigation. J Natl Cancer Inst. 1989 Mar 15; 81(6):402-3. PMID: 2918549.
    View in: PubMed
  135. Siegel RD, Ryan LM, Antman KH. Osteosarcoma in adults. One institution's experience. Clin Orthop Relat Res. 1989 Mar; (240):261-9. PMID: 2917442.
    View in: PubMed
  136. Weissmann LB, Antman KH. Incidence, presentation and promising new treatments for malignant mesothelioma. Oncology (Williston Park). 1989 Jan; 3(1):67-72; discussion 73-4, 77. PMID: 2701403.
    View in: PubMed
  137. Mick R, Begg CB, Antman KH, Korzun AH, Frei E. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat. 1989 Jan; 13(1):33-8. PMID: 2650758.
    View in: PubMed
  138. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31. PMID: 2491883.
    View in: PubMed
  139. Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol. 1988 Dec; 11(6):614-7. PMID: 3189226.
    View in: PubMed
  140. Rosenberg AE, Garber JE, Bennett W, Bhan AK, Antman KH, Mark EJ. Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review. Am J Clin Pathol. 1988 Dec; 90(6):723-6. PMID: 3057863.
    View in: PubMed
  141. Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst. 1988 Oct 5; 80(15):1221-6. PMID: 3138431.
    View in: PubMed
  142. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7. PMID: 3042045.
    View in: PubMed
  143. Antman K, Schnipper LE, Frei E. The crisis in clinical cancer research. Third-party insurance and investigational therapy. N Engl J Med. 1988 Jul 7; 319(1):46-8. PMID: 3288868.
    View in: PubMed
  144. Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol. 1988 Jun; 124(6):878-84. PMID: 3288124.
    View in: PubMed
  145. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009.
    View in: PubMed
  146. Talcott JA, Antman KH. Asbestos-related malignancy. Curr Probl Cancer. 1988 May-Jun; 12(3):135-78. PMID: 3067983.
    View in: PubMed
  147. Licht JD, Weissmann LB, Antman K. Gastrointestinal sarcomas. Semin Oncol. 1988 Apr; 15(2):181-8. PMID: 3285480.
    View in: PubMed
  148. Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med. 1988 Apr; 108(4):570-4. PMID: 3279894.
    View in: PubMed
  149. Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65. PMID: 3281213.
    View in: PubMed
  150. Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Combined modality treatment of peritoneal mesotheliomas. NCI Monogr. 1988; (6):321-2. PMID: 3352777.
    View in: PubMed
  151. Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988; 4(1):53-8. PMID: 3281212.
    View in: PubMed
  152. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988 Jan; 6(1):147-53. PMID: 3335886.
    View in: PubMed
  153. Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep. 1987 Nov; 71(11):1043-7. PMID: 3119200.
    View in: PubMed
  154. Constable JD, Timperi R, Clapp R, Antman K, Boynton B. Vietnam veterans and soft tissue sarcoma. J Occup Med. 1987 Sep; 29(9):726. PMID: 3681503.
    View in: PubMed
  155. Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer. 1987 Jun 1; 59(11):1882-6. PMID: 3567851.
    View in: PubMed
  156. Talcott J, Thurber W, Gaensler E, Antman K, Li FP. Mesothelioma in manufacturers of asbestos-containing cigarette filters. Lancet. 1987 Feb 14; 1(8529):392. PMID: 2880203.
    View in: PubMed
  157. Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25. PMID: 3542208.
    View in: PubMed
  158. Antman K, Eder JP, Frei E. High-dose chemotherapy with bone marrow support for solid tumors. Important Adv Oncol. 1987; 221-35. PMID: 2841230.
    View in: PubMed
  159. Wilson RE, Wood WC, Lerner HL, Antman K, Amato D, Corson JM, Proppe K, Harmon D, Carey R, Greenberger J, et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg. 1986 Nov; 121(11):1354-9. PMID: 3535741.
    View in: PubMed
  160. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7. PMID: 3534155.
    View in: PubMed
  161. Antman KH. Searching for truth--from biblical to modern times. J Clin Oncol. 1986 Oct; 4(10):1441-2. PMID: 3760918.
    View in: PubMed
  162. Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep. 1986 Jul; 70(7):877-80. PMID: 3719578.
    View in: PubMed
  163. Elias AD, Antman KH. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. Cancer Treat Rep. 1986 Jul; 70(7):827-33. PMID: 3087617.
    View in: PubMed
  164. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol. 1986 May; 4(5):646-54. PMID: 3517240.
    View in: PubMed
  165. Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet. 1986 Feb 15; 20(3-4):191-201. PMID: 3943062.
    View in: PubMed
  166. Antman KH. Asbestos-related malignancy. Crit Rev Oncol Hematol. 1986; 6(3):287-309. PMID: 3542255.
    View in: PubMed
  167. Kaye JA, Wang AM, Joachim CL, Seltzer SE, Cibas E, Skarin A, Antman KH. Malignant mesothelioma with brain metastases. Am J Med. 1986 Jan; 80(1):95-7. PMID: 3942156.
    View in: PubMed
  168. Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985 Nov 2; 2(8462):977-81. PMID: 2414612.
    View in: PubMed
  169. Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, Carey R, Greenberger J, Wilson R, Frei E. Selection bias in clinical trials. J Clin Oncol. 1985 Aug; 3(8):1142-7. PMID: 4020412.
    View in: PubMed
  170. Antman KH, Montella D, Rosenbaum C, Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep. 1985 May; 69(5):499-504. PMID: 3924401.
    View in: PubMed
  171. Kobzik L, Antman KH, Warhol MJ. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy. Acta Cytol. 1985 May-Jun; 29(3):219-25. PMID: 3859121.
    View in: PubMed
  172. Antman KH, Corson JM. Benign and malignant pleural mesothelioma. Clin Chest Med. 1985 Mar; 6(1):127-40. PMID: 3891207.
    View in: PubMed
  173. Antman K, Pomfret E, Karp G, Skarin A, Canellos G. Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep. 1984 Nov; 68(11):1413-4. PMID: 6094004.
    View in: PubMed
  174. Antman KH, Nadler L, Mark EJ, Montella DL, Kirkpatrick P, Halpern J. Primary Kaposi's sarcoma of the lung in an immunocompetent 32-year-old heterosexual white man. Cancer. 1984 Oct 15; 54(8):1696-8. PMID: 6478408.
    View in: PubMed
  175. Antman KH, Ruxer RL, Aisner J, Vawter G. Mesothelioma following Wilms' tumor in childhood. Cancer. 1984 Jul 15; 54(2):367-9. PMID: 6327010.
    View in: PubMed
  176. Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol. 1984 Jun; 2(6):601-8. PMID: 6374055.
    View in: PubMed
  177. Antman K, Cohen S, Dimitrov NV, Green M, Muggia F. Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol. 1984 May; 2(5):447-51. PMID: 6726298.
    View in: PubMed
  178. Wilson RE, Antman KH, Brodsky G, Greenberger JS. Tumor-cell heterogeneity in soft tissue sarcomas as defined by chemoradiotherapy. Cancer. 1984 Mar 15; 53(6):1420-5. PMID: 6692332.
    View in: PubMed
  179. Antman KH, Corson JM, Li FP, Greenberger J, Sytkowski A, Henson DE, Weinstein L. Malignant mesothelioma following radiation exposure. J Clin Oncol. 1983 Nov; 1(11):695-700. PMID: 6668488.
    View in: PubMed
  180. Grant DC, Seltzer SE, Antman KH, Finberg HJ, Koster K. Computed tomography of malignant pleural mesothelioma. J Comput Assist Tomogr. 1983 Aug; 7(4):626-32. PMID: 6863663.
    View in: PubMed
  181. Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol. 1983 Jun; 1(6):386-91. PMID: 6668506.
    View in: PubMed
  182. Antman KH, Blum RH, Wilson RE, Corson JM, Greenberger JS, Amato DA, Canellos GP, Frei E. Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer. 1983 Feb 1; 51(3):396-401. PMID: 6821825.
    View in: PubMed
  183. Antman KH, Corson J, Greenberger J, Wilson R. Multimodality therapy in the management of angiosarcoma of the breast. Cancer. 1982 Nov 15; 50(10):2000-3. PMID: 6889910.
    View in: PubMed
  184. Nauta RJ, Osteen RT, Antman KH, Koster JK. Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized. Ann Thorac Surg. 1982 Jul; 34(1):66-70. PMID: 7092403.
    View in: PubMed
  185. Devereux DF, Wilson RE, Carson JM, Antman KH, Greenberger JS. Surgical treatment of low grade soft tissue sarcomas. Am J Surg. 1982 Apr; 143(4):490-4. PMID: 7072914.
    View in: PubMed
  186. Whitley NO, Brenner DE, Antman KH, Grant D, Aisner J. CT of peritoneal mesothelioma: analysis of eight cases. AJR Am J Roentgenol. 1982 Mar; 138(3):531-5. PMID: 6978005.
    View in: PubMed
  187. Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys. 1982 Jan; 8(1):19-25. PMID: 6174494.
    View in: PubMed
  188. Antman KH, Parker LM, Goldstein JD, Skarin AT, D'Orsi CJ. Acute renal failure following intravenous pyelography (IVP) in a patient with diffuse hypergammaglobulinemia: a case report. Med Pediatr Oncol. 1982; 10(3):289-94. PMID: 7045616.
    View in: PubMed
  189. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981 Sep; 8(3):313-20. PMID: 7280715.
    View in: PubMed
  190. Karp G, Antman K, Canellos G. VP-16-213. A phase II trial using a weekly schedule. Cancer Clin Trials. 1981; 4(4):465-7. PMID: 7318129.
    View in: PubMed
  191. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep; 40(9):3147-54. PMID: 7427932.
    View in: PubMed
  192. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980 Jul 24; 303(4):200-2. PMID: 6155613.
    View in: PubMed
  193. Antman KH, Livingston DM. Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell. 1980 Mar; 19(3):627-35. PMID: 6244892.
    View in: PubMed
  194. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar; 68(3):356-62. PMID: 7361805.
    View in: PubMed
  195. Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84. PMID: 481196.
    View in: PubMed
Karen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department